These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23826595)

  • 1. Hepatitis C--an update.
    Holmes J; Thompson A; Bell S
    Aust Fam Physician; 2013 Jul; 42(7):452-6. PubMed ID: 23826595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Hepatitis C Infection in Children.
    Pham YH; Rosenthal P
    Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
    Northcott MJ; Ong WL; Walsh M; McCarthy P; Belleli D; Tran H; Street A; Kemp W; Davis AK
    Haemophilia; 2013 Nov; 19(6):847-52. PubMed ID: 23738855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
    Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
    Dutilh JC; Arends JE
    Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
    [No Abstract]   [Full Text] [Related]  

  • 6. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Berzsenyi MD; Roberts SK
    J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
    Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
    Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
    Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
    J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.
    Rutter K; Hofer H; Beinhardt S; Dulic M; Gschwantler M; Maieron A; Laferl H; Stättermayer AF; Scherzer TM; Strassl R; Holzmann H; Steindl-Munda P; Ferenci P
    Aliment Pharmacol Ther; 2013 Jul; 38(2):118-23. PubMed ID: 23710895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
    Ueyama M; Nakagawa M; Sakamoto N; Onozuka I; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Kitazume A; Murakawa M; Nishimura-Sakurai Y; Sekine-Osajima Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M;
    Antivir Ther; 2011; 16(7):1081-91. PubMed ID: 22024524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of chronic hepatitis C].
    Fehér J; Lengyel G
    Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
    [No Abstract]   [Full Text] [Related]  

  • 19. A step forward in therapy for hepatitis C.
    Hoofnagle JH
    N Engl J Med; 2009 Apr; 360(18):1899-901. PubMed ID: 19403908
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.